|
Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy Clinical research trials and Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy. Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy clinical trial. Human subjects often obtain the finest healthcare possible for their Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy  Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy
Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy
For Condition: unspecified adult solid tumor, protocol specific,Fatigue
Status: Suspended
Sponsor(s): M.D. Anderson Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Epoetin alfa may help improve energy levels and quality of life in patients who have advanced solid tumors. PURPOSE: Randomized clinical trial to study the effectiveness of epoetin alfa in treating fatigue in patients who are not receiving chemotherapy for advanced solid tumors.
Details: OBJECTIVES: - Determine the efficacy of epoetin alfa in treating fatigue in patients with advanced solid tumors who are not receiving chemotherapy. - Determine the efficacy of this drug on functional status and overall quality of life in these patients. - Correlate self-reported level of energy with other commonly occurring symptoms (e.g., pain, depression, anxiety, dyspnea, appetite disturbance, or sleep disturbance) in these patients. - Correlate anemia with other common symptoms in these patients. - Determine the internal consistency of fatigue self-report using three single-item measures of this symptom and the responsiveness of each item to change over time in these patients. OUTLINE: This is a double-blind, placebo-controlled, randomized, multicenter study. Patients are stratified according to participating center, ECOG performance status (0-1 vs 2-3), and hemoglobin prior to study (10 mg/dL or less vs greater than10 mg/dL). Patients are randomized to one of two treatment arms. - Arm I: Patients receive epoetin alfa subcutaneously (SC) once weekly for 6 weeks. - Arm II: Patients receive placebo SC once weekly for 6 weeks. Patients in either arm that do not respond to therapy may receive an additional 6 weeks of open-label epoetin alfa SC once weekly. In both arms, quality of life and fatigue are assessed at baseline and at 3 and 6 weeks. If patients receive an additional 6 weeks of therapy, quality of life and fatigue are also assessed at 9 and 12 weeks. PROJECTED ACCRUAL: A total of 128 patients (64 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of stage III or IV invasive non-myeloid malignancy - Not currently hospitalized - At least somewhat bothered by fatigue based on self-report - No significant psychological distress indicated by total score of 6 or more on questions 1 and 2 of the Three-Question Screening Survey (3QSS) - No score less than 2 on question 3 of 3QSS indicating low level of fatigue within the past week - No uncontrolled brain metastases or leptomeningeal involvement PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-3 Life expectancy: - At least 12 weeks Hematopoietic: - Hemoglobin at least 8.5 g/dL but no greater than 12 g/dL - No anemia due to factors other than cancer or chemotherapy (e.g., iron or folate deficiency, hemolysis, or bleeding) - No prior or concurrent hematological disease Hepatic: - Not specified Renal: - Not specified Cardiovascular: - No uncontrolled hypertension (diastolic blood pressure greater than 100 mm Hg or systolic blood pressure greater than 200 mm Hg) - No significant uncontrolled concurrent cardiovascular disease or dysfunction not attributable to malignancy or chemotherapy Pulmonary: - No significant uncontrolled concurrent pulmonary disease or dysfunction not attributable to malignancy or chemotherapy Other: - Not pregnant or nursing - Fertile patients must use effective contraception during and for 3 months after study participation - Able to understand and complete self-report symptom assessment forms in English - No serious concurrent infection - No known hypersensitivity to mammalian cell-derived products or human albumin - No uncontrolled seizures - No significant uncontrolled concurrent endocrine, neurologic, gastrointestinal, or genitourinary system disease or dysfunction not attributable to malignancy or chemotherapy PRIOR CONCURRENT THERAPY: Biologic therapy: - See Chemotherapy - More than 4 weeks since prior biologic therapy (e.g., interferon or interleukin-2) - More than 2 months since prior RBC transfusion - More than 1 month since prior epoetin alfa or investigational forms of epoetin alfa (e.g., gene-activated, novel erythropoiesis-stimulating protein) - Concurrent non-myelosuppressive therapy (e.g., monoclonal antibody infusions, antiangiogenesis inhibitors, or signal transduction inhibitors) allowed - No other concurrent biologic therapy Chemotherapy: - No prior high-dose chemotherapy (e.g., with bone marrow or stem cell transplantation) - More than 4 weeks since prior chemotherapy - No concurrent chemotherapy Endocrine therapy: - Concurrent hormonal therapy allowed (e.g., LHRH agonists or tamoxifen) Radiotherapy: - More than 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelFisch, Study Chair, M.D. Anderson Cancer Center
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224
United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
United States
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin, 54449
United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
CCOP - Dayton
Dayton, Ohio, 45429
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
CCOP - Greenville
Greenville, South Carolina, 29615
United States
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
Additional Information:
Study ID Numbers: CDR0000069409; MDA-DM-02331,MDA-DM-0038,NCI-P02-0225
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00052221
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer
2. Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
3. Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer
4. Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
5. Darbepoetin Alfa Compared With Epoetin alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Michigan Clinical Trials
Other Kalamazoo Clinical Trials
Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy
|
|
|
|
|
|
|
|
